| Background: Hyperuricemia(HUA)and gout are considerable public health problems because of their increasing incidence and interactions with other diseases.We aimed to evaluate the efficacy and safety of urate-lowering therapies(ULTs)for patients.Methods: A systematic literature review was conducted,and a network meta-analysis was performed on the included studies using the Markov Chain Monte Carlo simulation method and a Bayesian statistical framework.We calculated surface under the cumulative ranking curve(SUCRA)values and performed cluster ranking to combine the efficacy and safety results.Results: Twenty-two randomized controlled studies were identified for the efficacy analysis,and 20 studies were identified for the safety analysis.Compared with the placebo,the ULTs were efficient and safe.Febuxostat 120 mg/d and allopurinol 200 mg/d had the highest scores for efficacy and safety,respectively(79.8 and 88.9).Cluster ranking results showed that febuxostat 120 mg/d was the best in terms of efficacy and safety,topiroxostat 120/160 mg/d was similar to febuxostat 80 mg/d in terms of efficacy but safer.Conclusion: Febuxostat had the best efficacy and safety results among the tested agents,and topiroxostat and allopurinol appeared to have fewer adverse events.We prefer xanthine oxidase inhibitors(XOIs)for controlling sUA levels in hyperuricemia patients.Background: Myeloblastosis oncogene proto-oncogene like 2(MYBL2)is a transcription factor that is upregulated and significantly associated with various human cancer types.However,the potential role of MYBL2 in clear cell renal cell carcinoma(ccRCC)is yet to be elucidated.Therefore,the expression and biological functions of MYBL2 in ccRCC were assessed in the current study using The Cancer Genome Atlas(TCGA).Methods: A Wilcoxon signed?rank test was performed to compare MYBL2 expression between ccRCC and normal tissues.Moreover,the association between MYBL2 expression and various clinicopathological factors was estimated using both the Wilcoxon signed?rank test and logistic regression.The differences in prognosis between patients with high? and low?MYBL2 expression were analyzed via the Kaplan?Meier method and Cox regression analysis.Finally,gene set enrichment analysis(GSEA)was performed to investigate the biofunctions of MYBL2 in ccRCC.Results: It was revealed that MYBL2 was upregulated in ccRCC,and that the MYBL2 high?expression phenotype was significantly associated with sex,a high histological grade,an advanced clinical stage,tumor stage,lymph node metastasis,distant metastasis and poor overall survival(OS).It was also revealed,via the Cox regression analysis,that the upregulation of MYBL2 expression was able to independently predict a poor prognosis in patients with ccRCC.GSEA indicated that the intestinal immune network for Ig A production,primary immunodeficiency,the janus kinase(JAK)?signal transducer and activator of transcription(STAT)signaling pathway,the cytosolic DNA?sensing pathway,the p53 signaling pathway and the chemokine signaling pathway were all enriched in the high-MYBL2 expression datasets.Conclusion: The present findings indicate that MYBL2 may be used as an independent prognostic factor in patients with ccRCC. |
PDF Full Text Request